Search research articles
Contact Us
Filters
Showing results (41-50 of 70) with videos related to
Page
of 7
Sort By:
Molecular Cancer Therapeutics
|
January 30, 2016
Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
Colin D Weekes, Laetitia E Lamberts, Mitesh J Borad, et al.
Plos One
|
April 7, 2022
The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm
Amna Zafar, Zsofia D Drobni, Matthew Lei, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract
|
January 27, 2021
Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy
Theodoros Michelakos, Yurie Sekigami, Filippos Kontos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 23, 2020
A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors
Sara M Tolaney, Khanh T Do, Joseph P Eder, et al.
Nature Medicine
|
January 9, 2024
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial
Shubham Pant, Zev A Wainberg, Colin D Weekes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 5, 2014
Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies
Daniel W Bowles, Jennifer R Diamond, Elaine T Lam, et al.
JAMA Network Open
|
November 17, 2023
Patient-Reported Outcomes, Tumor Markers, and Survival Outcomes in Advanced GI Cancer
Joy X Jarnagin, Anurag Saraf, Islam Baiev, et al.
British Journal of Cancer
|
February 3, 2017
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor
Johanna C Bendell, Milind Javle, Tanios S Bekaii-Saab, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 2013
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer
Colin D Weekes, Daniel D Von Hoff, Alex A Adjei, et al.
Annals of Surgery
|
July 11, 2020
A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer: The PANAMA-score
Thomas Hank, Marta Sandini, Cristina R Ferrone, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 70) with videos related to
Sort By:
Page
of 7
Molecular Cancer Therapeutics
|
January 30, 2016
Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
Colin D Weekes, Laetitia E Lamberts, Mitesh J Borad, et al.
Plos One
|
April 7, 2022
The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm
Amna Zafar, Zsofia D Drobni, Matthew Lei, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract
|
January 27, 2021
Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy
Theodoros Michelakos, Yurie Sekigami, Filippos Kontos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 23, 2020
A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors
Sara M Tolaney, Khanh T Do, Joseph P Eder, et al.
Nature Medicine
|
January 9, 2024
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial
Shubham Pant, Zev A Wainberg, Colin D Weekes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 5, 2014
Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies
Daniel W Bowles, Jennifer R Diamond, Elaine T Lam, et al.
JAMA Network Open
|
November 17, 2023
Patient-Reported Outcomes, Tumor Markers, and Survival Outcomes in Advanced GI Cancer
Joy X Jarnagin, Anurag Saraf, Islam Baiev, et al.
British Journal of Cancer
|
February 3, 2017
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor
Johanna C Bendell, Milind Javle, Tanios S Bekaii-Saab, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 2013
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer
Colin D Weekes, Daniel D Von Hoff, Alex A Adjei, et al.
Annals of Surgery
|
July 11, 2020
A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer: The PANAMA-score
Thomas Hank, Marta Sandini, Cristina R Ferrone, et al.
Page
of 7